Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 235

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

Open access
van Imhoff, Gustaaf W., McMillan, Andrew, Matasar, Matthew J., Radford, John, Ardeshna, Kirit M., Kuliczkowski, Kazimierz, Kim, WonSeog, Hong, Xiaonan, Goerloev, Jette Soenderskov, Davies, Andrew, Barrigón, María Dolores Caballero, Ogura, Michinori, Leppä, Sirpa, Fennessy, Michael, Liao, Qiming, van der Holt, Bronno, Lisby, Steen, Hagenbeek, Anton · 2017 · Journal of Clinical Oncology

Abstract

Purpose: We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment, followed by autologous stem-cell transplantation (ASCT) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients and Methods: Patients with CD20+ DLBCL age ≥ 18 years who had experienced their first relapse or who were refractory to first-line R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)–like treatment were randomly assigned between three cycles of R-DHAP or O-DHAP. Either O 1,000 mg or R 375 mg/m 2 was administered for a total of four infusions (days 1 and 8 of cycle 1; day 1 of cycles 2 and 3 of DHAP). Patients who experienced a response after two cycles of treatment received the third cycle, followed by high-dose therapy and ASCT. Primary end point was progression-free survival (PFS), with failure to achieve a response after cycle 2 included as an event. Results: Between March 2010 and December 2013, 447 patients were randomly assigned. Median age was 57 years (range, 18 to 83 years); 17% were age ≥ 65 years; 63% had stage III and IV disease; 71% did not achieve complete response (CR) or experience response for < 1 year on first-line R-CHOP. Response rate for O-DHAP was 38% (CR, 15%) versus 42% (CR, 22%) for R-DHAP. ASCT on protocol was completed by 74 patients (33%) in the O arm and 83 patients (37%) in the R arm. PFS, event-free survival, and overall survival were not significantly different between O-DHAP versus R-DHAP: PFS at 2 years was 24% versus 26% (hazard ratio [HR], 1.12; 95% CI, 0.89 to 1.42; P = .33); event-free survival at 2 years was 16% versus 18% (HR, 1.10; P = .35); and overall survival at 2 years was 41% versus 38% (HR, 0.90; P = .38). Positron emission tomography negativity before ASCT was highly predictive for superior outcome. Conclusion: No difference in efficacy was found between O-DHAP and R-DHAP as salvage treatment of relapsed or refractory DLBCL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.69.0198

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 24

  1. 10.1056/NEJMoa011795 · DOI · Paper page
  2. 10.1200/JCO.2005.09.131 · DOI · Paper page
  3. 10.1016/S1470-2045(06)70664-7 · DOI · Paper page
  4. 10.1016/S1470-2045(08)70002-0 · DOI · Paper page
  5. 10.1200/JCO.2005.05.1003 · DOI · Paper page
  6. 10.1200/JCO.2005.09.137 · DOI · Paper page
  7. 10.1056/NEJM199512073332305 · DOI · Paper page
  8. 10.1182/blood-2007-08-108415 · doi:10.1182/blood-2007-08-108415
  9. 10.3324/haematol.13440 · DOI · Paper page
  10. 10.1200/JCO.2010.28.1618 · DOI · Paper page
  11. 10.4049/jimmunol.177.1.362 · DOI · Paper page
  12. 10.1111/j.1365-2141.2011.08966.x · DOI
  13. 10.1182/blood-2007-09-111781 · DOI · Paper page
  14. 10.1182/blood-2007-10-117671 · DOI · Paper page
  15. 10.1182/blood-2012-12-472027 · DOI
  16. 10.1182/blood-2002-12-3837 · DOI · Paper page
  17. 10.1200/JCO.2006.09.2403 · DOI · Paper page
  18. 10.1200/JCO.2006.08.2305 · DOI · Paper page
  19. 10.1200/JCO.1998.16.10.3264 · doi:10.1200/jco.1998.16.10.3264
  20. 10.1182/blood-2014-10-606939 · doi:10.1182/blood-2014-10-606939
  21. 10.1158/1078-0432.CCR-09-1624 · DOI · Paper page
  22. 10.1182/blood-2008-08-175208 · DOI · Paper page
  23. 10.1200/JCO.2013.53.9593 · DOI · Paper page
  24. 10.1038/nrclinonc.2014.137 · DOI

Cited by

See all 235

Metadata

Authors
van Imhoff, G. W., McMillan, A., Matasar, M. J., Radford, J., Ardeshna, K. M., Kuliczkowski, K., Kim, W., Hong, X., Goerloev, J. S., Davies, A., Barrigón, M. D. C., Ogura, M., Leppä, S., Fennessy, M., Liao, Q., van der Holt, B., Lisby, S., & Hagenbeek, A.
Venue
Journal of Clinical Oncology
Published
2017-02-10
Volume
35
Issue
5
Pages
544-551
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2565561569
Cited by
235
References
1
FWCI
15.21
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.